Press Releases

Archives: Search / 2017

2016201520142013201220112010200920082007

2012 Archives

Dec 19, 2012
- Companies Pledge to Make Results Publicly Accessible in an Effort to Accelerate Cancer Drug Development -

H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of oncology treatments, announced today that it has...

More
Dec 17, 2012

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced that it has entered into a definitive asset...

More
Dec 12, 2012
-- Deal Leverages Complementary Strengths for Both Research Triangle Park Employers --

Research Triangle Park, NC - December 12, 2012 - Biogen Idec (NASDAQ: BIIB) and Eisai Inc. today announced a strategic alliance that will bolster the manufacturing capabilities of both...

More
Dec 11, 2012

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) determined that Eisai has met the FDA's Written Request requirements...

More
Dec 7, 2012

Results from the first large, global Phase III study of Halaven(®) (eribulin mesylate) Injection in patients with early-stage metastatic breast cancer...

More
Nov 30, 2012

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review Eisai's New Drug Application (NDA)...

More
Nov 28, 2012

Eisai Inc. announced today that six abstracts highlighting new study results will be presented during the 2012 CTRC-AACR San Antonio Breast...

More
Nov 26, 2012

Following a productive first year of headcount growth and scientific advancement, H3 Biomedicine Inc. (H3), a biopharmaceutical company specializing...

More
Nov 19, 2012

In conjunction with Eisai Co., Ltd., the Eisai USA Foundation, the charitable arm of Eisai Inc., announced today that it will be making a...

More
Nov 12, 2012

Morphotek(® )Inc., a subsidiary of Eisai Inc., announced today that the United States Food and Drug Administration (FDA) has granted orphan drug...

More
Nov 8, 2012
Eisai Recognizes Inaugural LGS Awareness Day and Epilepsy Awareness Month with Launch of New Caregiver Support Video

With approximately two million people in the United States living with epilepsy, including a severe and rare form called Lennox-Gastaut syndrome...

More
Oct 22, 2012
-- FYCOMPA is the First FDA-Approved Non-competitive AMPA Glutamate Receptor Antagonist --

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved FYCOMPA (perampanel) as an adjunctive treatment for...

More
Oct 4, 2012
H3 Biomedicine is first partner for program aimed at generating 'first-in-class' patient-relevant targets based on synthetic lethality screens

Horizon Discovery Ltd (Horizon), a leading provider of research tools to support the development of personalized medicines,...

More
Oct 3, 2012
Campaign to Raise Research Funds for the 30 percent of Patients with Breast Cancer Who Will Develop Metastatic Disease

METAvivor Research and Support, Inc. and Eisai Inc. announced today the launch of "The Elephant in the Pink Room," a campaign...

More
Aug 27, 2012
Clinical Study Seeks to Evaluate MORAb-004 Plus the Standard of Care for Extending Progression-Free Survival of Patients with Metastatic Soft Tissue Sarcoma

Morphotek(®), Inc. announced today that it has commenced a multi-center, Phase II study evaluating the safety and efficacy of MORAb-004 when combined...

More
Aug 20, 2012

Eisai Inc. announced today that the results of two studies: "Evaluation of Adjunctive Perampanel in Patients with Refractory Partial Onset...

More
Aug 14, 2012
Facility Will Help Accelerate Early-Stage Clinical Trials of Biologics

Morphotek(®), Inc., a wholly-owned subsidiary of Eisai Co., Ltd., today celebrated the grand opening of a new pilot manufacturing plant for the...

More
Aug 8, 2012
Together The Eisai Women's Oncology Program, CANCERcare, Cancer Support Community and Meals On Wheels Association of America Are Working to Help Ease the Stress of Those Living with Breast Cancer

Woodcliff Lake, NJ, Augugst 8, 2012 - Magnolia Meals at Home™, a new program bringing free, nutritious meals to patients living with breast cancer and their families, is now being piloted in and...

More
Jul 30, 2012
Eisai Plans to Submit Applications for Marketing Approval throughout the Americas

WOODCLIFF LAKE, NJ, and SAN DIEGO, CA, July 30, 2012 -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that Arena has transferred the BELVIQ® (lorcaserin hydrochloride)...

More
Jul 25, 2012

Eisai Inc. announced today that the results of the study, "Adjunctive Perampanel For Refractory Partial-Onset Seizures: Randomized Phase III...

More
Jul 9, 2012

Eisai Inc. today announced preliminary results from a recently completed phase III study of Halaven versus capecitabine (Xeloda®) in women with...

More
Jun 27, 2012
-- First Prescription Weight-Loss Treatment Approved by FDA in 13 Years -- Eisai to Launch BELVIQ in U.S. Following DEA's Completion of Scheduling Review --

San Diego, CA, and Woodcliff Lake, NJ, June 27, 2012 - Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved...

More
Jun 22, 2012

Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Shaji Procida to the position of...

More
May 30, 2012
Company Recognized for Outstanding Contributions to the Pharmaceutical Sciences

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that The American Association of Pharmaceutical Scientists (AAPS) has awarded its 2012...

More
May 17, 2012

Eisai announced today that 15 abstracts highlighting new study results will be presented during the 48(th) Annual Meeting of the American Society...

More
 

print email rss